The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
- PMID: 15385929
- DOI: 10.1038/sj.leu.2403513
The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
Abstract
Ethical and scientific concerns regarding the use of human fetal bones in the SCID-hu model of primary human myeloma prompted us to develop a novel system that uses rabbit bones implanted subcutaneously in unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts and osteoblasts were of rabbit origin. The implanted bones were directly injected with myeloma cells from 28 patients. Successful engraftment of unseparated BM cells from 85% of patients and CD138-selected myeloma plasma cells from 81% of patients led to the production of patients' M-protein isotypes and typical myeloma manifestations (osteolytic bone lesions and angiogenesis of rabbit origin). Myeloma cells grew exclusively in the rabbit bone, but were able to metastasize into another bone at a remote site in the same mouse. Cells from patients with extramedullary disease also grew along the outer surface of the rabbit bones. This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. This system can now be widely used to study the biology of myeloma and its manifestations and to develop novel therapeutic approaches for this disease.
Similar articles
-
The SCID-hu myeloma model.Methods Mol Med. 2005;113:183-90. doi: 10.1385/1-59259-916-8:183. Methods Mol Med. 2005. PMID: 15968103
-
High heparanase activity in multiple myeloma is associated with elevated microvessel density.Cancer Res. 2003 Dec 15;63(24):8749-56. Cancer Res. 2003. PMID: 14695190
-
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.Cancer. 2003 Feb 1;97(3 Suppl):802-12. doi: 10.1002/cncr.11134. Cancer. 2003. PMID: 12548579 Review.
-
Syndecan-1 in B lymphoid malignancies.Ann Hematol. 2002 Mar;81(3):125-35. doi: 10.1007/s00277-002-0437-8. Epub 2002 Mar 1. Ann Hematol. 2002. PMID: 11904737 Review.
-
Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.Mod Pathol. 2001 Oct;14(10):1052-8. doi: 10.1038/modpathol.3880435. Mod Pathol. 2001. PMID: 11598177
Cited by
-
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice.JCI Insight. 2024 May 7;9(10):e177300. doi: 10.1172/jci.insight.177300. JCI Insight. 2024. PMID: 38713510 Free PMC article.
-
Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.Front Immunol. 2023 Aug 14;14:1195194. doi: 10.3389/fimmu.2023.1195194. eCollection 2023. Front Immunol. 2023. PMID: 37646021 Free PMC article. Review.
-
Current and Future PET Imaging for Multiple Myeloma.Life (Basel). 2023 Aug 7;13(8):1701. doi: 10.3390/life13081701. Life (Basel). 2023. PMID: 37629558 Free PMC article. Review.
-
Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.Front Oncol. 2022 Aug 5;12:894279. doi: 10.3389/fonc.2022.894279. eCollection 2022. Front Oncol. 2022. PMID: 35992875 Free PMC article.
-
CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence.Int J Hematol. 2022 Mar;115(3):336-349. doi: 10.1007/s12185-021-03261-0. Epub 2022 Feb 8. Int J Hematol. 2022. PMID: 35133572
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous